Schering-Plough completes enrolment of pivotal hepatitis C trial
This article was originally published in Scrip
Executive Summary
Schering-Ploughhas announced the completion of patient enrolment for its pivotal Phase III study HCV SPRINT-2, testing its protease inhibiting hepatitis C drug candidate boceprevir in combination with standard therapy in treatment-naïve patients.